Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs. “It’s been a transformative start to the year, leading to significant enhancements in how we are building value going forward,” said B
Click here to view original post